218 related articles for article (PubMed ID: 11956259)
1. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
[TBL] [Abstract][Full Text] [Related]
2. The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?
Allgayer H; Aguirre-Ghiso JA
APMIS; 2008; 116(7-8):602-14. PubMed ID: 18834405
[TBL] [Abstract][Full Text] [Related]
3. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
[TBL] [Abstract][Full Text] [Related]
5. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol.
Allgayer H; Heiss MM; Riesenberg R; Babic R; Jauch KW; Schildberg FW
J Histochem Cytochem; 1997 Feb; 45(2):203-12. PubMed ID: 9016310
[TBL] [Abstract][Full Text] [Related]
7. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer.
Buergy D; Fuchs T; Kambakamba P; Mudduluru G; Maurer G; Post S; Tang Y; Nakada MT; Yan L; Allgayer H
Cancer; 2009 Oct; 115(20):4667-78. PubMed ID: 19569245
[TBL] [Abstract][Full Text] [Related]
9. CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy.
Noack F; Helmecke D; Rosenberg R; Thorban S; Nekarda H; Fink U; Lewald J; Stich M; Schutze K; Harbeck N; Magdolen V; Graeff H; Schmitt M
Int J Oncol; 1999 Oct; 15(4):617-23. PubMed ID: 10493940
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bone marrow micrometastases in patients with gastric cancer.
Jauch KW; Heiss MM; Gruetzner U; Funke I; Pantel K; Babic R; Eissner HJ; Riethmueller G; Schildberg FW
J Clin Oncol; 1996 Jun; 14(6):1810-7. PubMed ID: 8656249
[TBL] [Abstract][Full Text] [Related]
11. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
Tögel F; Datta C; Badbaran A; Kröger N; Renges H; Gieseking F; Jänicke F; Zander AR; Krüger W
J Hematother Stem Cell Res; 2001 Feb; 10(1):141-5. PubMed ID: 11276367
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
[TBL] [Abstract][Full Text] [Related]
14. Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years.
Slade MJ; Singh A; Smith BM; Tripuraneni G; Hall E; Peckitt C; Fox S; Graham H; Lüchtenborg M; Sinnett HD; Cross NC; Coombes RC
Int J Cancer; 2005 Mar; 114(1):94-100. PubMed ID: 15523696
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
16. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease.
Laufs S; Schumacher J; Allgayer H
Cell Cycle; 2006 Aug; 5(16):1760-71. PubMed ID: 16931909
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
19. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer.
Kim SJ; Shiba E; Taguchi T; Watanabe T; Tanji Y; Kimoto Y; Izukura M; Takai SI
Anticancer Res; 1997; 17(2B):1373-8. PubMed ID: 9137501
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
